SCHEMBL996970

SCHEMBL996970

CCOC(=O)C1CCC=CCCCCCN(Cc2ccc(OC)cc2)C(=O)[N+]2CC(O[Si](C)(C)C(C)(C)C)CC2C(=O)N1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 3/20 0.33
▸ KCNH2 Q12809 2/20 0.33
▸ ALDH1A1 P00352 6/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MMP1 P03956 1/20 0.32
▸ MMP13 P45452 1/20 0.32
▸ CYP2C9 P11712 2/20 0.32
▸ CYP2C19 P33261 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ POLB P06746 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ USP2 O75604 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ HSP90AA1 P07900 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3528218 0.92 MMP1 (0.34) MCHR1KCNH2ALDH1A1HRH3MMP1
SCHEMBL3526341 0.87 ALDH1A1 (0.34) MCHR1KCNH2ALDH1A1HRH3L3MBTL1
SCHEMBL995887 0.87 ALDH1A1 (0.36) ALDH1A1HRH3L3MBTL1MMP1MMP13
SCHEMBL994826 0.82 ALDH1A1 (0.35) KCNH2ALDH1A1MMP1MEN1KMT2A
SCHEMBL3308918 0.82 MCHR1 (0.35) MCHR1KCNH2ALDH1A1HRH3L3MBTL1
SCHEMBL3314022 0.81 ALDH1A1 (0.32) MCHR1KCNH2ALDH1A1HRH3CYP2C9
SCHEMBL995145 0.80 MMP1 (0.34) ALDH1A1HRH3L3MBTL1MMP1MMP13
SCHEMBL2839916 0.79 ALDH1A1 (0.33) MCHR1KCNH2ALDH1A1CYP2C9CYP2C19
SCHEMBL2837719 0.78 KCNH2 (0.31) MCHR1KCNH2
SCHEMBL996316 0.76 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919898-B1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARM LTD (IE) 2011-01-26 — — EP disclosed
US-7666834-B2 Macrocyclic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-02-23 — — US disclosed
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus HCCS, CBR1, CYP2B6 MCHR1 1785/4885KCNH2 2258/4885ALDH1A1 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback